LINE241220P60000
- 0.55
- 0.000.00%
Lineage Newsroom
J.P. Morgan Remains a Buy on Lineage, Inc. (LINE)
Wells Fargo Maintains Lineage(LINE.US) With Hold Rating
Analysts Offer Insights on Healthcare Companies: Lineage Therap (LCTX), Veeva Systems (VEEV) and Takeda Pharmaceutical Company (TAK)
D. Boral Capital Initiates Coverage On Lineage Cell Therapeutics With Buy Rating, Announces Price Target of $3
Lineage Cell Therapeutics Analyst Ratings
Goldman Sachs Maintains Lineage(LINE.US) With Buy Rating, Cuts Target Price to $89
Lineage Is Maintained at Outperform by RBC Capital
RBC Capital Maintains Lineage(LINE.US) With Buy Rating, Cuts Target Price to $81
Craig-Hallum Keeps Their Buy Rating on Lineage Therap (LCTX)
Piper Sandler Maintains Lineage(LINE.US) With Buy Rating, Cuts Target Price to $90
Lineage Is Maintained at In-Line by Evercore ISI Group
Lineage Analyst Ratings
Scotiabank Maintains Lineage(LINE.US) With Buy Rating, Cuts Target Price to $94
Truist Financial Maintains Lineage(LINE.US) With Buy Rating, Maintains Target Price $94
Evercore Maintains Lineage(LINE.US) With Hold Rating, Cuts Target Price to $78
Baird Maintains Lineage(LINE.US) With Buy Rating, Cuts Target Price to $85
Morgan Stanley Maintains Lineage(LINE.US) With Buy Rating, Maintains Target Price $100
Truist Financial Maintains Lineage(LINE.US) With Buy Rating, Maintains Target Price $94
Lineage, Inc. Stabilizes Amid Challenges: Buy Rating Justified by Steady Performance and Potential for Recovery
Piper Sandler Maintains Lineage(LINE.US) With Buy Rating, Maintains Target Price $102